Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 2.3700 |
| Open | 2.3900 |
| Bid | 2.3000 x 36900 |
| Ask | 2.3600 x 39400 |
| Day's range | 2.2700 - 2.4750 |
| 52-week range | 1.3800 - 9.9600 |
| Volume | |
| Avg. volume | 7,121,593 |
| Market cap | 540.537M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. EDT to discuss financial results and provide a general business update.
- PR Newswire
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced that it has implemented a corporate reorganization designed to extend its cash runway and to focus on key clinical programs with the goal to drive long-term growth.
- PR Newswire
INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan (the "In
